Literature DB >> 20649640

Advanced glycation end-products and the kidney.

Martin Busch1, Sybille Franke, Christiane Rüster, Gunter Wolf.   

Abstract

BACKGROUND: Advanced glycation end-products (AGEs) are increased in situations with hyperglycemia and oxidative stress such as diabetes mellitus. They are products of nonenzymatic glycation and oxidation of proteins and lipids. The kidney plays an important role in clearance and metabolism of AGEs.
METHODS: Medline and other relevant databases were searched. In addition, key review articles were scanned for relevant original publication. Finally, original data from our research group were also included.
RESULTS: Kidney podocytes and endothelial cells express specific receptors for AGEs. Their activation leads to multiple pathophysiological effects including hypertrophy with cell cycle arrest and apoptosis, altered migration, and generation of proinflammatory cytokines. AGEs have been primarily implicated in the pathophysiology of diabetic nephropathy and diabetic microvascular complications. AGEs are also involved in other primary renal diseases as well as in the development and progression of atherosclerosis. However, serum or plasma concentrations of AGEs do not correlate well with cardiovascular events in patients with chronic kidney disease (CKD). This is likely due to the fact that serum concentrations failed to correlate with AGEs deposited in target tissues. Several inhibitors of the AGE-RAGE axis are currently tested for various indications.
CONCLUSION: AGEs and their receptors are involved in the pathogenesis of vascular and kidney disease. The role of circulating AGEs as biomarkers for cardiovascular risk estimation is questionable. Whether putative inhibitors of AGEs will get the maturity for its therapeutic use in the future remains open.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649640     DOI: 10.1111/j.1365-2362.2010.02317.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  50 in total

1.  Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.

Authors:  Sokho Kim; Jungkee Kwon
Journal:  J Physiol       Date:  2015-02-27       Impact factor: 5.182

2.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

Review 3.  Diabetic nephropathy and extracellular matrix.

Authors:  S O Kolset; F P Reinholt; T Jenssen
Journal:  J Histochem Cytochem       Date:  2012-10-27       Impact factor: 2.479

4.  Periodontitis predicts elevated C-reactive protein levels in chronic kidney disease.

Authors:  E Ioannidou; H Swede; A Dongari-Bagtzoglou
Journal:  J Dent Res       Date:  2011-09-22       Impact factor: 6.116

5.  Garrod's fourth inborn error of metabolism solved by the identification of mutations causing pentosuria.

Authors:  Sarah B Pierce; Cailyn H Spurrell; Jessica B Mandell; Ming K Lee; Sharon Zeligson; Michael S Bereman; Sunday M Stray; Siv Fokstuen; Michael J MacCoss; Ephrat Levy-Lahad; Mary-Claire King; Arno G Motulsky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

6.  Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.

Authors:  Takanori Matsui; Sae Nakashima; Yuri Nishino; Ayako Ojima; Nobutaka Nakamura; Kazunari Arima; Kei Fukami; Seiya Okuda; Sho-ichi Yamagishi
Journal:  Lab Invest       Date:  2015-03-02       Impact factor: 5.662

Review 7.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

8.  Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease.

Authors:  Eun Young Park; Bo Hye Kim; Eun Ji Lee; EunSun Chang; Dae Won Kim; Soo Young Choi; Jong Hoon Park
Journal:  J Biol Chem       Date:  2014-02-10       Impact factor: 5.157

9.  Skin autofluorescence and all-cause mortality in stage 3 CKD.

Authors:  Simon D S Fraser; Paul J Roderick; Natasha J McIntyre; Scott Harris; Christopher W McIntyre; Richard J Fluck; Maarten W Taal
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 8.237

Review 10.  The role of chronic kidney disease-associated dysbiosis in cardiovascular disease.

Authors:  Mark A Bryniarski; Fares Hamarneh; Rabi Yacoub
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.